• Cancer Cells Can Flood Bloodstream with Protein ‘Warriors’ Against Immune Response, Study Finds
  • New Method Uses Bioinformatics to Monitor Immunotherapy Response to Cancer
  • FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo for Advanced Endometrial Carcinoma
  • Seattle Children’s Hospital Enrolling Patients with Advanced Solid Tumors for Study of CAR T-cell Immunotherapy
  • FDA Grants Fast Track Designation to Galinpepimut-S for Treating Multiple Myeloma
  • BioLineRx Initiates Phase 1/2a Trial Testing AGI-134 in Metastatic Solid Tumors
  • Advaxis to Open Phase 1 Trial of ADXS-503, Potential Immunotherapy for Metastatic NSCLC
  • FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer
  • New IO Therapies Reach Cancer Patients in 4 Months, But Study Warns That Speed May Raise Risks
  • Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for Colorectal Cancer
  • FDA Expedites Tecentriq-Avastin Combo for Most Common Liver Cancer
  • Activating Brain’s Reward System Reduces Tumor Size in Mice, Study Reports